Valuation : Immuneering Corporation

Market Cap 312M 268M 252M 230M 430M 29.57B 432M 2.98B 1.16B 15.11B 1.17B 1.15B 47.94B P/E 2026 *
-4.27x
P/E 2027 * -3.81x
Enterprise Value 312M 268M 252M 230M 430M 29.57B 432M 2.98B 1.16B 15.11B 1.17B 1.15B 47.94B EV / Sales 2026 *
-
EV / Sales 2027 * 16x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Immuneering Corporation

1 day-0.83%
1 week-4.21%
Current month-4.21%
1 month+5.99%
3 months+11.94%
6 months-10.32%
Current year-27.36%
1 week 4.68
Extreme 4.685
5.1
1 month 4.51
Extreme 4.51
5.43
Current year 3.86
Extreme 3.86
8.48
1 year 3.86
Extreme 3.86
10.08
3 years 1
Extreme 1
10.08
5 years 1
Extreme 1
33.25
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 31/01/2008
Director of Finance/CFO 61 15/07/2026
Chief Tech/Sci/R&D Officer - 31/07/2023
Director TitleAgeSince
Chairman 81 31/12/2007
Director/Board Member 44 31/01/2008
Director/Board Member 72 26/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Other

Chief Financial Officer

225,000 0.3478%
16/07/26 Free

Chief Financial Officer

650,000 1.0047%
13/03/26 Free

Head of Human Resources

3,628 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-4.21%-13.25%-43.03% 312M
+2.02%+1.01%+45.58%+104.91% 67.82B
-0.41%-1.12%+35.32%+80.68% 63.22B
-1.11%+2.52%-13.93%+369.69% 27.58B
-4.92%-2.90%-12.27%-17.60% 26.06B
+1.69%+0.94%+33.46%+17.80% 25.38B
+1.12%+2.03%+23.61%-17.59% 19.89B
+6.04%+0.72%+239.13%+407.95% 17.4B
-0.49%-1.85%-6.87%+546.36% 14.95B
-2.27%+5.55%+52.24%+161.90% 14.62B
Average +0.08%+1.91%+38.30%+161.11% 27.72B
Weighted average by Cap. +0.29%+1.54%+38.80%+143.11%

Financials

2026 *2027 *
Net sales - 19.5M 16.77M 15.78M 14.4M 26.88M 1.85B 27.02M 187M 72.26M 945M 73.2M 71.62M 3B
Net income -74.1M -63.74M -59.97M -54.73M -102M -7.03B -103M -709M -275M -3.59B -278M -272M -11.39B -85.92M -73.9M -69.54M -63.45M -118M -8.15B -119M -822M -318M -4.16B -323M -316M -13.21B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
57
Date Price Change Volume
08/09/26 US$4.780 -0.83% 1,032,830
04/09/26 US$4.820 -4.37% 1,000,331
03/09/26 US$5.040 +0.40% 424,432
02/09/26 US$5.020 +3.51% 678,701
01/09/26 US$4.850 -2.81% 435,184
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.780USD
Average target price
17.17USD
Spread / Average Target
+259.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!